DCTD Functional Genomics

该项目是癌症治疗和诊断科开发治疗计划药物发现和开发计划的重要组成部分。重点放在临床前药物发现和临床前药物开发上。 功能基因组学实验室(LFG) 功能基因组学实验室(LFG)为筛查技术科(STB)、开发治疗计划(DTP)、药物发现和开发工作提供专门的研究支持。基因组学技术，包括寡核苷酸微阵列、TaqMan(R)实时聚合酶链式反应、报告基因分析、多重基因分析和RNAi被用作确定特定基因在药物作用机制中的作用的工具。这些方法为探索新药作用机制的初步认识或更高级阶段的临床前药物的详细分析提供了重要的资源。该实验室为小企业或校内外科学家提供合作资源，努力将新药带到临床。此外，在这一领域获得的专业知识使该实验室在提出一个以NCI-60细胞系筛查药物反应的基因图谱为中心的大型项目中发挥了关键作用。此外，根据DTP或临床治疗评估计划(CTEP)的要求，LFG提供临床前、体外药物组合研究，以评估潜在临床药物组合可能希望或不希望发生的相互作用。

This project is a major part of the Developmental Therapeutics Program drug discovery and development program within the Division of Cancer Treatment and Diagnosis. The emphasis is on preclinical drug discovery and preclinical drug development. LABORATORY OF FUNCTIONAL GENOMICS (LFG) The Laboratory of Functional Genomics (LFG) provides dedicated research support for the Screening Technologies Branch (STB), Developmental Therapeutics Program (DTP), drug discovery and development effort. Genomic techniques, including oligonucleotide microarrays, TaqMan(R) real-time PCR, reporter gene assays, mutiplexing gene assays, and RNAi are used as tools to determine the role of specific genes in the mechanisms of drug action. These methods have provided an important resource to probe for preliminary insights into mechanism of action of novel agents, or detailed analyses with preclinical drugs at a more advanced stage. The laboratory offers a resource for small businesses or extra- and intramural scientists to collaborate in an effort to bring new drugs to the clinic. Moreover, the expertise gained in this area has allowed the laboratory to play a critical role in proposing a large-scale project centered on gene profiling of drug responses in the NCI-60 cell line screen. In addition, the LFG provides preclinical, in vitro drug combination studies for evaluation of possible desirable or undesirable interactions for potential clinical drug combinations, as requested by DTP or the Clinical Therapy Evaluation Program (CTEP).